HKHenna Karra

Henna Karra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Henna Karra has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival

    by Heli Repo, Natalia Gurvits, Eliisa Löyttyniemi, Marjukka Nykänen, Minnamaija Lintunen, Henna Karra, Samu Kurki, Teijo Kuopio, Kati Talvinen, Mirva Söderström, et al.

    PTTG1-interacting protein (PTTG1IP) is an oncogenic protein, which participates in metaphase-anaphase transition of the cell cycle through activation of securin (PTTG1). PTTG1IP promotes the shift of securin from the cell cytoplasm to the nucleus, allowing the interaction between separase and securin. PTTG1IP overexpression has been previously observed in malignant disease, e.g. in breast carcinoma. However, the prognostic value of PTTG1IP in breast carcinoma patients has not previously been revealed. A total of 497 breast carcinoma patients with up to 22-year follow-up were analysed for PTTG1IP and securin immunoexpression. The results were evaluated for correlations with the clinical prognosticators and patient survival. In our material, negative PTTG1IP immunoexpression predicted a 1.5-fold risk of breast cancer death (p = 0.02). However, adding securin immunoexpression to the analysis indicated an even stronger and independent prognostic power in the patient material (HR = 2.5, p < 0.0001). The subcellular location of securin was found with potential prognostic value also among the triple-negative breast carcinomas (n = 96, p = 0.052). PTTG1IP-negativity alone and in combination with high securin immunoexpression indicates a high risk of breast cancer death, resulting in up to 14-year survival difference in our material.


  • Open Access

    Cdc20 and securin overexpression predict short-term breast cancer survival

    by H Karra, H Repo, I Ahonen, E Löyttyniemi, R Pitkänen, M Lintunen, T Kuopio, M Söderström, P Kronqvist

    Cdc20 is an essential component of cell division and responsible for anaphase initiation regulated by securin degradation. Cdc20 function is strongly regulated by the spindle assembly checkpoint to ensure the timely separation of sister chromatids and integrity of the genome. We present the first results on Cdc20 in a large clinical breast cancer material. The study was based on 445 breast cancer patients with up to 20 years of follow-up (mean 10.0 years). DNA content was determined by image cytometry on cell imprints, and Cdc20 and securin immunohistochemistry on tissue microarrays of breast cancer tissue. In our results, high Cdc20 and securin expression was associated with aneuploid DNA content. In prognostic analyses, high Cdc20 immunoexpression alone and in combination with high securin immunoexpression indicated aggressive course of disease and up to 6.8-fold (P<0.001) risk of breast cancer death. Particularly, high Cdc20 and securin immunoexpression identified a patient subgroup with extremely short, on average 2.4 years, breast cancer survival and triple-negative breast cancer (TNBC) subtype. We report for the first time the association of high Cdc20 and securin immunoexpression with extremely poor outcome of breast cancer patients. Our experience indicates that Cdc20 and securin are promising candidates for clinical applications in breast cancer prognostication, especially in the challenging prognostic decisions of TNBC.


  • Securin predicts aneuploidy and survival in breast cancer

    by Henna Karra, Reino Pitkänen, Marjukka Nykänen, Kati Talvinen, Teijo Kuopio, Mirva Söderström, Pauliina Kronqvist

    Karra H, Pitkänen R, Nykänen M, Talvinen K, Kuopio T, Söderström M & Kronqvist P (2012) Histopathology 60, 586–596 Securin predicts aneuploidy and survival in breast cancerAims:  Securin is known to participate in maintaining chromosomal integrity during the cell cycle through regulation of metaphase–anaphase transition, DNA damage repair, and apoptosis. The aim of this study was to investigate the role of securin in aneuploidy and prognosis in human breast cancer.Methods and results:  The study was based on 603 breast cancer patients with up to 20 years of follow‐up. DNA content was determined by image cytometry on cell imprints, and securin immunohistochemistry was performed on tissue microarrays of breast cancer tissue. We show, for the first time in human breast cancer, that high‐level securin expression predicts abnormal DNA content, with up to 9.8‐fold odds for aneuploid DNA content (P = 0.0007). Securin also shows strong independent prognostic value for disease‐specific survival, with a significant difference in survival time between patients with low‐level and high‐level securin expression.Conclusions:  The main result of the present study is the association of aneuploidy and securin expression. According to our results, securin immunohistochemistry is also a potential new prognosticator for treatment decisions concerning breast cancer patients.